Bilateral Acute Depigmentation of Iris (BADI) Post COVID Infection following Systemic Moxifloxacin Therapy

ABSTRACT

Purpose

To report a case of BADI post Covid infection following systemic moxifloxacin therapy.

Methods

Observational case study.

Case report

A 28-year-old female presented to us with complaints of redness and pain in the right eye since 5 days. History revealed use of systemic moxifloxacin for covid infection. She was managed with topical corticosteroids and cycloplegics following a diagnosis of BADI.

Conclusion

Bilateral acute depigmentation of iris (BADI) is a rare disease entity associated with the release of iris pigments. Various underlying aetiologies have been associated with the same. Although BADI is a benign, self-limiting disorder, it needs to be differentiated with other potential severe clinical entities. SARS-CoV2 has been associated with various ocular manifestations. However, to the best of our knowledge, BADI has never been associated with COVID infection yet. We report a case of BADI in a young healthy Asian middle – aged female 3 months after an acute COVID infection.

KEYWORDS:

• Bilateral acute depigmentation of iris (BADI)
• bilateral acute iris transillumination (BAIT)
• herpetic iridocyclitis
• pigment dispersion syndrome (PDS)
• SARS-CoV2

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.